The Female Sexual Dysfunction drugs in development market research report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Female Sexual Dysfunction. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued products.
GlobalData tracks 22 drugs in development for Female Sexual Dysfunction by 15 companies/universities/institutes. The top development phase for Female Sexual Dysfunction is preclinical with eight drugs in that stage. The Female Sexual Dysfunction pipeline has 21 drugs in development by companies and one by universities/ institutes. Some of the companies in the Female Sexual Dysfunction pipeline products market are: S1 Biopharma, Kuhnil Pharmaceutical and Initiator Pharma.
The key targets in the Female Sexual Dysfunction pipeline products market include Androgen Receptor, Sodium Dependent Dopamine Transporter, and Sodium Dependent Serotonin Transporter.
The key mechanisms of action in the Female Sexual Dysfunction pipeline product include Androgen Receptor Agonist with four drugs in Phase III. The Female Sexual Dysfunction pipeline products include 12 routes of administration with the top ROA being Oral and four key molecule types in the Female Sexual Dysfunction pipeline products market including Small Molecule, and Synthetic Peptide.
Female Sexual Dysfunction overview
Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure, and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.
For a complete picture of Female Sexual Dysfunction’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
